Pleasant Ridge Hemp

05/08/2026

𝐓𝐡𝐞 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐚𝐧𝐝 𝐬𝐚𝐟𝐞𝐭𝐲 𝐨𝐟 𝐜𝐚𝐧𝐧𝐚𝐛𝐢𝐝𝐢𝐨𝐥 𝐚𝐬 𝐚𝐝𝐣𝐮𝐧𝐜𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐝𝐫𝐮𝐠‐𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐢𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐞𝐩𝐢𝐥𝐞𝐩𝐬𝐲 𝐢𝐧 𝟓𝟏 𝐝𝐨𝐠𝐬: 𝐀 𝐝𝐨𝐮𝐛𝐥𝐞‐𝐛𝐥𝐢𝐧𝐝𝐞𝐝 𝐜𝐫𝐨𝐬𝐬𝐨𝐯𝐞𝐫 𝐬𝐭𝐮𝐝𝐲
Rozental, et al

Results
At the 9 mg/kg/day dose, the decrease in total seizure frequency was significant compared with placebo. A 24.1% decrease in seizure days occurred in dogs receiving CBD and a 5.8% increase occurred in dogs receiving placebo (P ≤ .05). No significant difference was found in the number of responders (≥50% decrease in total seizures or seizure days). Liver enzyme activities increased at both dosages. Decreased appetite and vomiting were more common in the CBD phase (P ≤ .05).

Conclusions and Clinical Importance
Cannabidiol decreased total seizures and seizure days compared to placebo when administered to dogs PO at 9 mg/kg/day. Liver enzymes should be monitored with administration of CBD in dogs.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10658598/

05/07/2026

Results
Twenty-five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6–479.4); CBD/CBDA 403.4 nM/h (351.9–462.5)] but was different at week 5 [placebo 572.6 (448.3–731.2); CBD/CBDA 406.8 (3.23.2–551.8)]. CBD/CBDA supplementation was well-tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences.

Conclusion and Clinical Importance
Short-term oral CBD/CBDA-rich h**p supplementation appeared safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma.

AbstractBackground. The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich h**p oil supplementation in dogs with cancer receiving chemothe

04/11/2026

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

02/10/2026

State Senator Patrick Testin (R-Stevens Point) is spearheading a legislative push to define the future of Wisconsin’s dinner plates and... Read More

02/10/2026

12/19/2025

How about that?!?!

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

11/17/2025

Love our customers!!

11/14/2025

The U.S. House of Representatives has approved a Senate-passed spending bill that includes provisions to ban most consumable h**p products, sending it to President Donald Trump’s desk. Following a historic, weeks-long government shutdown, the Senate approved the appropriations legislation on Monda...

07/22/2025

:)

06/26/2025

Don’t miss out! There’s still time to order and receive an additional 20% off before the end of this month!

Need help sleeping? Have pain? Need something to calm that anxiety?

Try CBD!

06/11/2025

https://pleasantridgeglobal.com/so/59PTV5S7Z?languageTag=en

Pleasant Ridge Global, LLC